Cargando…
EphA2 Expression in Bone Sarcomas: Bioinformatic Analyses and Preclinical Characterization in Patient-Derived Models of Osteosarcoma, Ewing’s Sarcoma and Chondrosarcoma
Bone sarcomas are a group of heterogeneous malignant mesenchymal tumors. Complete surgical resection is still the cornerstone of treatment, but, in the advanced/unresectable setting, their management remains challenging and not significantly improved by target- and immuno-therapies. We focused on th...
Autores principales: | Giordano, Giorgia, Merlini, Alessandra, Ferrero, Giulio, Mesiano, Giulia, Fiorino, Erika, Brusco, Silvia, Centomo, Maria Laura, Leuci, Valeria, D’Ambrosio, Lorenzo, Aglietta, Massimo, Sangiolo, Dario, Grignani, Giovanni, Pignochino, Ymera |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616526/ https://www.ncbi.nlm.nih.gov/pubmed/34831119 http://dx.doi.org/10.3390/cells10112893 |
Ejemplares similares
-
PARP1 Inhibitor and Trabectedin Combination Does Not Increase Tumor Mutational Burden in Advanced Sarcomas—A Preclinical and Translational Study
por: Pignochino, Ymera, et al.
Publicado: (2021) -
Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy.
por: Mesiano, Giulia, et al.
Publicado: (2018) -
CD44v6 as innovative sarcoma target for CAR-redirected CIK cells
por: Leuci, V., et al.
Publicado: (2018) -
DNA damage response and repair genes in advanced bone and soft tissue sarcomas: An 8-gene signature as a candidate predictive biomarker of response to trabectedin and olaparib combination
por: Merlini, Alessandra, et al.
Publicado: (2022) -
Activity of cytokine-induced killer cells against bone and soft tissue sarcoma
por: Sangiolo, Dario, et al.
Publicado: (2014)